

Alzheimer's Association International Conference®

Los Angeles, USA
July 12–13: Preconferences
July 14–18: Annual Conference

9 posters
8 oral presentations

1. **P2-33 9** Association between brain network dynamics and plasma biomarkers in cognitively intact individuals at risk for Alzheimer's disease
2. **P1-230** Memory function is associated to Tau pathology in Parkinson's disease.
3. **P2-253** Ante-Mortem CSF α -Synuclein Predicts Time until Death in an Autopsy Cohort
4. **P2-256** **NPTX2** Levels in CSF As Potential Predictor of Cognitive Dysfunction in the AD Continuum
5. **P2-034** **Plasma Beta-Secretase 1 Concentrations** Predict Global and Regional Brain Burden of Amyloid- β in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies
6. **P2-258** An Amyloid-Coupled Pre-Dementia Increased CSF **Neurogranin/BACE1** Ratio May Reflect Early Synapse Affection in ApoE- ϵ 4 Homozygotes
7. **P4-021** **Plasma Beta-Secretase 1** Concentrations Impact Plasma NFL Concentrations in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies
8. **P1-230** Memory function is associated with **Tau** pathology in Parkinson's disease
9. **P4-705** Toward re-calibration of commercial immunoassays using certified reference materials for **A β 42 in human cerebrospinal fluid**
10. **F1-03-01** CSF Biomarkers Related to Neurodegeneration As Predictors of Cognitive Progression in MCI and Elderly Controls Abstract: Potential value of cerebrospinal fluid levels of **neuronal pentraxin 2** levels as a predictor of for cognitive dysfunction
11. **O1-0704** Biomarkers of **Amyloid, Tau and Synaptic Damage (Neurogranin, SNAP25)** and Interneuron-Dependent Synaptic Homeostasis (**NPTX2**) in CSF As Predictors of Cognitive Progression in MCI and AD
12. **O1-09-05** Sexual Dimorphism in **Plasma Beta-Secretase 1** Concentrations in Cognitively Normal Individuals at Risk for AD: Cross-Sectional and Longitudinal Studies
13. **O3-12-03** The CSF Synaptic Biomarker **BACE1** Correlates with Cognition in MCI and Alzheimer Disease
14. **O5-05-02** CSF Biomarkers of Synaptic Damage (**Neurogranin, SNAP25**) and Interneuron-Dependent Synaptic Homeostasis (**NPTX2**) Improve Diagnostic Classification of MCI and AD and Correlate with Cognition
15. **O2-05-03** Characterization and Transfer of a novel **A β 1-42/A β 1-40** Simoa Assay for integration into the Clinic.
16. **F1-05-01** Lab-related pre-analytical factors influencing **Plasma Amyloid Beta** concentrations
17. **F2-07-04** **Plasma Amyloid Beta 1-42 and 1-40** Measured by a Novel Simoa Assay as a Diagnostic tool for Alzheimer's disease pathology

